2. Kannel WR, Abbott RD. 1984. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N EngI J Med 311: 1144 - 1147.
3. Medalie JH, Goldbourt U. 1976. Unrecognized myocardial infarction: five-year inci- dence, mortality, and risk factors. Ann Intern Med 84: 526 - 531.
4. Shaper G, Cook DG, Walker M, Macfarlane PW. 1984. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J 51: 595 - 605.
5. Yano K, MacLean CJ. 1989. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 149: 1528 - 1532.
6. Nadelmann J, Frishman WH, Ooi WL et al. 1990. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older:
The Bronx Aging Study. Am J Cardiol 66: 533 - 537.
86
Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. 1995. Unrecognized myocar- dial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik study. Ann Intern Med 122: 96 - 102.
8. WHO MONICA Project. 1994. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case- fatality rates in 38 populations from 21 countries in four continents. Circulation 90: 583 -612.
9. Norris RM on behalf of the UKHAS Group. 1995. Mortality from ischaemic heart disease outside hospital: more bad news from the UK Heart Attack Study (UKHAS). Br Heart J 73(suppl 3): 50.
10. Soler NG, Bennett MA, Pentecost BL. 1975. Myocardial infarction in diabetics. Q J Med 44: 125-132.
11. Chamberlain DA. 1994. B-Blockers and calcium antagonists. In: Julian DG, Braunwald E (eds). Management of Acute Myocardial Infarction. WB Saunders, London.
12. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
13. Hirsh J, Fuster V. 1994. Guide to anticoagulant therapy part 2: oral anticoagulants. Circulation 89: 1469-1480.
14. Findlay 1, Cunningham D, Dargie H. 1994. Coronary heart disease, the menopause, and hormone replacement therapy. Br Heart J 71: 213 - 214.
15. Anti platelet Trialists Collaboration. 1994.Collaborative overview of randomised trials of antiplatelet therapy - 1: prevention of death, myocardial infarction,and stroke by pro- longed anti platelet therapy in various categories of patients. Br Med J 30S: 81 - 106.
16. Simoons ML. 1994. Myocardial infarction: ACE-inhibitors for all? Forever? [Edito- rial]. Lancet 344: 279-280.
17. Hopper JL, Pathik B, Hunt D, Chan WWC. 1989. Improved prognosis since 1969 of myocardial infarction treated in a coronary care unit: lack of relation with changes in severity. Br Med J 299: 892-896.
18.Wannamethee G, Whincup PH, Shaper AG, Walker M. 1995. Factors determining case fatality in myocardial infarction. "Who dies in a heart attack?" Br Heart J 74: 324 - 331.
19. De Bacquer D, Martins Pereira LS, De Backer G et al. 1994<*•The predictive value of electrocardiographic abnormalities for total and cardiovascular disease mortality in men and women. Eur Heart J 15: 1604 - 1610.
20. Mangano DT. Goldman L. 1995. Preoperative assessment of patients with known or suspected coronary disease. N EngI J Med 333: 1750 - 1756.
21. Pyorala К, De Backer G, Graham 1 et al. on behalf of the Task Force. 1994. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Soci- ety of Hypertension. Eur Heart J 15: 1300-1331.
87
Уважаемый посетитель!
Чтобы распечатать файл, скачайте его (в формате Word).
Ссылка на скачивание - внизу страницы.